Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.47 |
| ▸ | XBP1 | P17861 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663657 | 0.85 | GAA (0.61) | MAPTGAAKDM4ESYKTSHR | |
| SCHEMBL1428472 | 0.84 | MAPT (0.59) | MAPTGAAKDM4ETSHRTDP1 | |
| SCHEMBL3786692 | 0.83 | GLA (0.53) | MAPTGAAKDM4ESYKTSHR | |
| SCHEMBL112468 | 0.81 | MAPT (0.78) | MAPTGAAKDM4ETSHRTDP1 | |
| SCHEMBL31095359 | 0.81 | MAPT (0.78) | MAPTGAAKDM4ETSHRTDP1 | |
| SCHEMBL14439923 | 0.81 | SYK (0.50) | MAPTGAAKDM4ESYKTSHR | |
| SCHEMBL2227815 | 0.79 | MAPT (0.50) | MAPTGAAKDM4ESYKTSHR | |
| SCHEMBL347279 | 0.79 | MAPT (0.63) | MAPTGAAKDM4ETSHRTDP1 | |
| Hydrochloric Acid SCHEMBL4945295 | 0.79 | MAPT (0.81) | MAPTGAAKDM4ETSHRTDP1 | |
| SCHEMBL1311327 | 0.79 | TSHR (0.50) | MAPTGAAKDM4ETSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827616-B2 | Heterocyclic compounds as pesticides | DISCOVERY PURCHASER CORPORATION (US) | 2023-11-28 | — | — | US | disclosed |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| CN-112218878-A | NTCP inhibitors | 北京生命科学研究所 | 2021-01-12 | — | — | CN | disclosed |
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2020-12-31 | — | — | US | disclosed |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2020-08-11 | — | — | US | disclosed |
| US-20200062729-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | DISCOVERY PURCHASER CORPORATION | 2020-02-27 | — | — | US | disclosed |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2019-02-21 | — | — | US | disclosed |
| US-10106507-B2 | Potent dual BRD4-kinase inhibitors as cancer therapeutics | H. Lee Moffitt Cancer Center and Research Insitute, Inc. (US) | 2018-10-23 | — | — | US | disclosed |
| US-20180290984-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-10-11 | — | — | US | disclosed |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-08-10 | — | — | US | disclosed |
| WO-2017066428-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017066428-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2016022460-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | BAYLISS TRACY | 2007-06-14 | — | — | US | disclosed |
| CN-1902201-A | Bicyclic pyrimidin-4-(3H)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (VR1) | MERCK SHARP & DOHME (GB) | 2007-01-24 | — | — | CN | disclosed |
| EP-1687306-A1 | BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LTD. (GB) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005049613-A1 | BICYCLIC PYRIMIDIN-4-(3H)-ONES AND ANALOGUES AND DERIVATIVES THEREOF WHICH MODULATE THE FUNCTION OF THE VANILLOID-1 RECEPTOR (VR1) | MERCK SHARP & DOHME LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407328-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | MAPT 3403/4885GAA 4639/4885KDM4E 115/4885 |
| US-10738016-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | MAPT 3403/4885GAA 4639/4885KDM4E 115/4885 |
| US-20180290984-A1 | BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | MAPT 3403/4885GAA 4639/4885KDM4E 115/4885 |
| US-10106507-B2 | Potent dual BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | MAPT 3059/4885GAA 4168/4885KDM4E 116/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | MAPT 3312/4885GAA 1755/4885KDM4E 2606/4885 |
| US-11827616-B2 | Heterocyclic compounds as pesticides | DDT, CHRM1, ACHE | MAPT 4816/4885GAA 3273/4885KDM4E 1052/4885 |
| US-20070135454-A1 | Bicyclic pyrimidin-4(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1-receptor(vr1) | TRPV1, TRPV2, TRPV4 | MAPT 4636/4885GAA 4363/4885KDM4E 4401/4885 |
| US-20190055203-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | MAPT 3059/4885GAA 4168/4885KDM4E 116/4885 |
| US-11643396-B2 | BRD4-kinase inhibitors as cancer therapeutics | BRD4, BICRA, BRDT | MAPT 3403/4885GAA 4639/4885KDM4E 115/4885 |
| US-20170226065-A1 | POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS | BRD4, BICRA, BRDT | MAPT 3059/4885GAA 4168/4885KDM4E 116/4885 |
| US-20200062729-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | CHRM1, DDT, ACHE | MAPT 4783/4885GAA 3385/4885KDM4E 1061/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.